Evidence map›Paper›PMID 41751910›Full record

ArticleInternational journal of molecular sciences2026

Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on

Madison Bittner, Marta Llaurado Fernandez, Joshua Hoenisch, Yuen Yee Leung, Hannah Kim, Nelson K Y Wong, Kathleen I Pishas, Dane Cheasley, Karla J Cowley, Kaylene J Simpson and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Madison BittnerDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC V6H 3N1, Canada.ORCID 0000-0001-6530-4361
Marta Llaurado FernandezDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC V6H 3N1, Canada.
Joshua HoenischDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC V6H 3N1, Canada.
Yuen Yee LeungDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC V6H 3N1, Canada.ORCID 0009-0003-9958-5714
Hannah KimDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC V6H 3N1, Canada.
Nelson K Y WongDepartment of Experimental Therapeutics, BC Cancer, Vancouver, BC V5Z 1L3, Canada.ORCID 0000-0002-7003-6020
Kathleen I PishasPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Dane CheasleyPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Karla J CowleyVictorian Centre for Functional Genomics, Peter MacCallum Cancer Center, Melbourne, VIC 3000, Australia.ORCID 0000-0001-9757-2627
Kaylene J SimpsonVictorian Centre for Functional Genomics, Peter MacCallum Cancer Center, Melbourne, VIC 3000, Australia.ORCID 0000-0001-9136-1781
Yen-Yi LinVancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada.
Stanislav VolikVancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada.
Stephane Le BihanVancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada.ORCID 0000-0003-0648-8695
Colin C CollinsVancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada.
Martin KöbelDepartment of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
Mark S CareyDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC V6H 3N1, Canada.

Funding

Alberta Precision Laboratories RS21-608and RS21-609the BC Cancer Foundation (BCCF); the Medical Research Future Fund MRF1200264Therapeutic Innovation Australia (TIA); Victorian Cancer Agency MCRF19046
6 · The paper itself

Abstract

Low-grade serous ovarian carcinoma (LGSOC) usually presents in advanced stages and is associated with a high mortality rate. Clinical trials targeting the MAPK and cell cycle pathways in LGSOC have shown promising results for its treatment, however there is a need to improve efficacy and define predictive biomarkers to guide patient selection for treatment using these agents. We therefore evaluated cell cycle protein expression by immunohistochemistry (IHC) in 186 LGSOC cases, and evaluated the efficacy of the MEK inhibitor, trametinib, in combination with the CDK4/6 inhibitor, palbociclib, in preclinical models of LGSOC. Abnormal p16 expression was observed in 20% of primary and 46% of recurrent tumors, and it was associated with poorer survival (log-rank

Indexed as

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Cystadenocarcinoma, SerousMutationOvarian NeoplasmsProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)AnimalsCell Line, TumorCell ProliferationCyclin-Dependent Kinase Inhibitor p16FemaleHumansNeurofibromin 1PiperazinesPyridinesCDK4 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase Inhibitor p16KRAS protein, humanNeurofibromin 1NF1 protein, humanpalbociclibPiperazinesProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)PyridinesPyridonesPyrimidinonestrametiniblow-grade serous ovarian carcinomaMAPKovarian cancerp16/CDKN2Apalbociclibtargeted therapiestrametinib

Identifiers

PMID41751910
PMCPMC12940316

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.